Teriparatide Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants

Doh, Re-Mee; Park, Hye Jeong; Rhee, Yumie; Kim, Hyun Sil; Huh, Jisun; Park, Wonse

doi:10.1097/id.0000000000000232

Cited by 16 publications

(22 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Accordingly, these clinical and experimental data might be related to the successful use of human recombinant parathyroid hormone (rhPTH), a bone anabolic strategy, as a therapeutic approach for BONJ in the clinic. (Doh et al 2015;Khan et al 2015). (Santini et al 2003).…”

Section: Discussionmentioning

confidence: 99%

Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw

Córdova

Guilbaud

Amiaud

et al. 2016

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential contribution to the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BONJ) remain controversial. We assessed the effects of zoledronic acid (ZOL) on bone and vascular cells of the alveolar socket using a mouse model of BONJ. Material and methods: Thirty-two mice were treated twice a week with either 100 mu g/kg of ZOL or saline for 12 weeks. The first left maxillary molar was extracted at the third week. Alveolar sockets were assessed at both 3 weeks (intermediate) and 9 weeks (long-term) after molar extraction by semi quantitative histomorphometry for empty lacunae, preosteoblasts (Osterix), osteoclasts (TRAP), and pericyte-like cells (CD146). Also, the bone microarchitecture was assessed by micro-CT. Results: Osteonecrotic-like lesions were observed in 21% of mice. Moreover, a decreased number of preosteoblasts contrasted with the increased number of osteoclasts at both time points. In addition, osteoclasts display multinucleation and detachment from the endosteal surface. Furthermore, the number of pericyte-like cells increased at the intermediate time point. The alveolar bone mass increased exclusively with long-term ZOL treatment. Conclusion: The severe imbalance between bone-forming cells and bone-resorbing cells shown in this study could contribute to the pathogenesis of BONJ

show abstract

Section: Discussionmentioning

confidence: 99%

Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw

Córdova

Guilbaud

Amiaud

et al. 2016

Journal of Cranio-Maxillofacial Surgery

View full text Add to dashboard Cite

show abstract

“…(Doh et al, 2015;Kakehashi et al, 2015;Neuprez, Rompen, Crielaard, & Reginster, 2014). (Doh et al, 2015;Kakehashi et al, 2015;Neuprez, Rompen, Crielaard, & Reginster, 2014).…”

Section: Medical Management Of Onjmentioning

confidence: 99%

“…Therapeutic strategies for ONJ include a wide range of therapeutic options, from conservative treatments to surgical procedures. (Doh et al, 2015;Kakehashi et al, 2015;Neuprez, Rompen, Crielaard, & Reginster, 2014). Teriparatide treatment can produce favourable results even in previously refractory ONJ .…”

Section: Medical Management Of Onjmentioning

confidence: 99%

Antiresorptive treatment-associated ONJ

Eleutherakis‐Papaiakovou

Bamias

2017

Eur J Cancer Care

View full text Add to dashboard Cite

Osteonecrosis of the jaw (ONJ) is a severe complication of therapy with antiresorptive agents (e.g. bisphosphonates and denosumab), which are used to manage bone metastases from cancer, to reduce the incidence of skeletal-related events. Available data indicate that 0-27, 5% of patients exposed to antiresorptive agents may develop ONJ, depending on the number of infusions and the duration of therapy. Besides antiresorptive therapy, a number of risk factors for osteonecrosis have been identified. Oral surgical procedures, tooth extractions and infection to the jawbones are considered the main risk factors for developing ONJ, when receiving antiresorptive therapy. However, a growing number of patients develop ONJ without apparent risk factors, raising concern for other predisposing factors. Jaw bone necrosis may be irreversible, resulting in a chronic disease with negative impact on the quality of patients' lives. The role of risk reduction strategies like meticulous dental screening and optimal oral hygiene is fundamental for preventing development of ONJ. ONJ is usually treated conservatively to relieve the symptoms and manage jaw bone necrosis. In certain cases, surgical intervention is required. Future research should emphasize individual predisposition to ONJ, more effective preventive measures and more efficient therapeutic procedures.

show abstract

“…Many previous studies have shown that the intermittent administration of PTH (1-34) increases the systemic bone mass, strength, and BMD (Hock, Gera, Fonseca, & Raisz, 1988;Shen et al, 1998), prevents bone loss (Liu & Kalu, 1990), facilitates the healing of bone fractures (Aspenberg et al, 2010), and also reverses the reductions in the number and activity of osteoblasts induced by radiotherapy (Chandra et al, 2014). In dentistry, the intermittent administration of PTH inhibits periodontitis by preventing alveolar bone loss (Marques et al, 2005;Miller, Hunziker, Mecham, & Wronski, 1997), enhances osseous wound healing (Bashutski et al, 2010), and prevents and treats medication-related osteonecrosis of the jaw (Doh et al, 2015;Kim et al, 2014;Kuroshima, Entezami, McCauley, & Yamashita, 2014). The intermittent administration of PTH (1-34) also enhances bone formation of the implants and bone graft materials used in both orthopedics and dentistry (Almagro et al, 2013;Ohkawa, Tokunaga, & Endo, 2008).…”

Section: Introductionmentioning

confidence: 99%

Effect of teriparatide on early sinus graft healing in the ovariectomized rabbit

Dam

Jung

Park

et al. 2020

Clinical Oral Implants Res

Self Cite

View full text Add to dashboard Cite

Objectives The purpose of this study was to determine the effect of administering intermittent parathyroid hormone 1–34 [teriparatide, (PTH)] on the maxillary sinus lift and bone grafting in osteoporotic rabbits induced by ovariectomy and glucocorticoid. Materials and methods Ovariectomies were performed on 20 female New Zealand white rabbits that were randomly divided into two groups: (a) the PTH group (n = 10), in which 10 μg kg−1 day−1 PTH was injected subcutaneously 5 days a week for 5 weeks (from 1 week before until 4 weeks after sinus surgery), and (b) the saline group (n = 10), in which saline substituted PTH at the same dose, mode of administration, and duration. Bone grafting with bovine bone mineral was augmented into 13 sinuses, and bone grafts and implants were simultaneously performed in seven sinuses, in both groups. Animals were sacrificed at 4 weeks after surgery. To determine whether PTH was an effective treatment for osteoporosis, we measured the bone mineral density (BMD) of the right femur using micro‐computed tomography and performed radiographic and histometric analyses of the maxillary sinus surgery site. The Mann–Whitney test was used for statistical analysis. Results It was found that BMD increased in the femur, whereas none of the radiographic and histometric parameters differed significantly between the groups in the sinus, while there were large interindividual variations within groups. Conclusions These findings suggest that intermittent PTH does not promote new bone formation in the augmented maxillary sinus of ovariectomized rabbits.

show abstract

Teriparatide Therapy for Bisphosphonate-Related Osteonecrosis of the Jaw Associated With Dental Implants

Cited by 16 publications

References 18 publications

Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw

Severe compromise of preosteoblasts in a surgical mouse model of bisphosphonate-associated osteonecrosis of the jaw

Antiresorptive treatment-associated ONJ

Effect of teriparatide on early sinus graft healing in the ovariectomized rabbit

Contact Info

Product

Resources

About